Our findings suggest that exposure to EMsOI increases the levels of the pro-inflammatory factor Interleukin-9, potentially worsening EMs, while reducing the levels of pro-inflammatory factors IL-13 and IL-31. The gene discussed is IL31; the disease is eosinophilia-myalgia syndrome.